KR102336378B1 - Azd9291을 포함하는 제약 조성물 - Google Patents

Azd9291을 포함하는 제약 조성물 Download PDF

Info

Publication number
KR102336378B1
KR102336378B1 KR1020167020731A KR20167020731A KR102336378B1 KR 102336378 B1 KR102336378 B1 KR 102336378B1 KR 1020167020731 A KR1020167020731 A KR 1020167020731A KR 20167020731 A KR20167020731 A KR 20167020731A KR 102336378 B1 KR102336378 B1 KR 102336378B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical
parts
weight
agent
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167020731A
Other languages
English (en)
Korean (ko)
Other versions
KR20160101720A (ko
Inventor
데이비드 윌슨
신디 피니
스티븐 안토니 로우
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50191689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102336378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20160101720A publication Critical patent/KR20160101720A/ko
Application granted granted Critical
Publication of KR102336378B1 publication Critical patent/KR102336378B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167020731A 2014-01-02 2015-01-02 Azd9291을 포함하는 제약 조성물 Active KR102336378B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
GB1400034.3 2014-01-02
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (2)

Publication Number Publication Date
KR20160101720A KR20160101720A (ko) 2016-08-25
KR102336378B1 true KR102336378B1 (ko) 2021-12-08

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167020731A Active KR102336378B1 (ko) 2014-01-02 2015-01-02 Azd9291을 포함하는 제약 조성물

Country Status (37)

Country Link
US (6) US10183020B2 (enExample)
EP (1) EP3089741B1 (enExample)
JP (1) JP6588915B2 (enExample)
KR (1) KR102336378B1 (enExample)
CN (2) CN114712362A (enExample)
AR (1) AR098989A1 (enExample)
AU (1) AU2015204218B2 (enExample)
CA (1) CA2933403C (enExample)
CL (1) CL2016001609A1 (enExample)
CR (1) CR20160310A (enExample)
CY (1) CY1124848T1 (enExample)
DK (1) DK3089741T3 (enExample)
DO (1) DOP2016000156A (enExample)
EA (1) EA034243B9 (enExample)
ES (1) ES2873226T3 (enExample)
GB (1) GB201400034D0 (enExample)
GT (1) GT201600142A (enExample)
HR (1) HRP20210749T1 (enExample)
HU (1) HUE054344T2 (enExample)
IL (1) IL246186B (enExample)
LT (1) LT3089741T (enExample)
MX (1) MX367358B (enExample)
MY (1) MY183536A (enExample)
NI (1) NI201600098A (enExample)
NZ (1) NZ721298A (enExample)
PE (1) PE20161170A1 (enExample)
PH (1) PH12016501310B1 (enExample)
PL (1) PL3089741T3 (enExample)
PT (1) PT3089741T (enExample)
RS (1) RS61927B1 (enExample)
SG (1) SG11201605339QA (enExample)
SI (1) SI3089741T1 (enExample)
SM (1) SMT202100330T1 (enExample)
TW (1) TWI702953B (enExample)
UY (1) UY35933A (enExample)
WO (1) WO2015101791A1 (enExample)
ZA (1) ZA201605300B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
KR20220130249A (ko) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
MX2020008395A (es) * 2018-02-12 2020-09-21 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.
PL3758708T3 (pl) * 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
JP7095108B2 (ja) 2018-03-23 2022-07-04 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド 医薬組成物、その製造方法及び使用
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
KR20240168418A (ko) 2022-03-31 2024-11-29 아스트라제네카 아베 암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
AU2023262556A1 (en) 2022-04-28 2024-12-05 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
CA3259492A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
IL318241A (en) 2022-07-08 2025-03-01 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF receptor inhibitors for cancer treatment
IL321931A (en) 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
WO2025092926A1 (zh) * 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037763A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2013014448A1 (en) 2011-07-27 2013-01-31 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
IL163642A0 (en) 2002-02-26 2005-12-18 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
BRPI0814542A2 (pt) * 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
HRP20230529T1 (hr) * 2012-01-13 2023-09-15 Xspray Pharma Ab (Publ) Farmaceutski pripravak nilotinib
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037763A1 (en) 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
WO2013014448A1 (en) 2011-07-27 2013-01-31 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Also Published As

Publication number Publication date
US20190111057A1 (en) 2019-04-18
IL246186A0 (en) 2016-07-31
PH12016501310B1 (en) 2022-07-06
US20240189310A1 (en) 2024-06-13
TW201609101A (zh) 2016-03-16
NI201600098A (es) 2016-12-20
AU2015204218A1 (en) 2016-07-07
CY1124848T1 (el) 2022-11-25
JP6588915B2 (ja) 2019-10-09
DOP2016000156A (es) 2016-08-15
AR098989A1 (es) 2016-06-22
KR20160101720A (ko) 2016-08-25
DK3089741T3 (da) 2021-06-07
EA034243B1 (ru) 2020-01-21
CN105848647A (zh) 2016-08-10
CA2933403A1 (en) 2015-07-09
ZA201605300B (en) 2022-10-26
US10183020B2 (en) 2019-01-22
CL2016001609A1 (es) 2016-12-09
CR20160310A (es) 2016-09-23
US20160324854A1 (en) 2016-11-10
PE20161170A1 (es) 2016-11-24
HRP20210749T1 (hr) 2021-06-25
WO2015101791A1 (en) 2015-07-09
NZ721298A (en) 2017-10-27
MY183536A (en) 2021-02-25
PL3089741T3 (pl) 2021-09-27
ES2873226T3 (es) 2021-11-03
EP3089741A1 (en) 2016-11-09
US20200360378A1 (en) 2020-11-19
LT3089741T (lt) 2021-06-10
CN105848647B (zh) 2022-04-26
CN114712362A (zh) 2022-07-08
PH12016501310A1 (en) 2016-09-14
MX367358B (es) 2019-08-16
EA201691242A1 (ru) 2016-12-30
SI3089741T1 (sl) 2021-08-31
RS61927B1 (sr) 2021-06-30
HUE054344T2 (hu) 2021-08-30
US20220395502A1 (en) 2022-12-15
EA034243B9 (ru) 2020-04-10
TWI702953B (zh) 2020-09-01
CA2933403C (en) 2022-03-29
IL246186B (en) 2020-07-30
MX2016008744A (es) 2016-09-08
HK1225655A1 (zh) 2017-09-15
PT3089741T (pt) 2021-06-11
GB201400034D0 (en) 2014-02-19
AU2015204218B2 (en) 2017-06-15
SMT202100330T1 (it) 2021-07-12
JP2017501201A (ja) 2017-01-12
US20250017930A1 (en) 2025-01-16
UY35933A (es) 2015-07-31
GT201600142A (es) 2019-08-12
EP3089741B1 (en) 2021-03-10
SG11201605339QA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US20250017930A1 (en) Pharmaceutical compositions comprising azd9291
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
US20220168255A1 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
WO2006070781A1 (ja) 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法
EP2964200B1 (en) Formulations of organic compounds
KR102197465B1 (ko) 디메틸푸마르산염을 함유한 장용성 정제
SG172191A1 (en) Capecitabine rapidly disintegrating tablets
US20110086102A1 (en) Delayed release compositions
EP3796908B1 (en) Controlled release propiverine formulations
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
JP6739289B2 (ja) ゲフィチニブを有効成分とする医薬錠剤の製造方法
HK1228245B (en) Pharmaceutical compositions comprising azd9291
HK1225655B (en) Pharmaceutical compositions comprising azd9291
US11786527B2 (en) Pharmaceutical composition and preparation method therefor and uses thereof
US20080206329A1 (en) Modified Release Ciprofloxacin Compositions
BR112016014348B1 (pt) Composição farmacêutica, uso da dita composição, comprimido farmacêutico e uso do dito comprimido
WO2019138346A1 (en) Pharmaceutical composition of osimertinib
HK1212244B (en) Formulations of organic compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20250924

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2336378

Appeal request date: 20241025

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100003116

Decision date: 20250924

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2336378

Appeal request date: 20241108

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024100003260

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024100003116; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

Free format text: ST27 STATUS EVENT CODE: A-5-5-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024100003260; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5